[Form 4] Aptevo Therapeutics Inc Insider Trading Activity
Jeffrey G. Lamothe, identified as EVP and COO of Aptevo Therapeutics (APVO), was granted 17,300 restricted stock units (RSUs) on 08/06/2025. Each RSU converts one-for-one into common stock, the grant is recorded as an acquisition of derivative securities at a reported price of $0.00, and the filing shows 17,300 shares of direct beneficial ownership following the transaction.
The RSUs vest in full on the first anniversary of the grant date, so conversion into common shares is contingent on that vesting event. The Form 4 discloses this equity award and the resulting change in the reporting person's beneficial ownership for SEC transparency.
Jeffrey G. Lamothe, indicato come EVP e COO di Aptevo Therapeutics (APVO), ha ricevuto il 08/06/2025 17.300 restricted stock units (RSU). Ogni RSU si converte uno a uno in azioni ordinarie; la concessione 猫 registrata come acquisizione di titoli derivati a un prezzo riportato di $0.00, e il deposito mostra 17.300 azioni di propriet脿 diretta a seguito della transazione.
Le RSU maturano integralmente al primo anniversario della data di attribuzione, quindi la conversione in azioni ordinarie 猫 subordinata a tale evento di maturazione. Il Modulo 4 comunica questo premio azionario e la conseguente variazione della propriet脿 effettiva della persona che effettua la comunicazione per garantire la trasparenza verso la SEC.
Jeffrey G. Lamothe, identificado como EVP y COO de Aptevo Therapeutics (APVO), recibi贸 el 08/06/2025 17.300 unidades restringidas (RSU). Cada RSU se convierte una a una en acciones ordinarias; la concesi贸n se registra como adquisici贸n de valores derivados a un precio declarado de $0.00, y la presentaci贸n muestra 17.300 acciones de propiedad directa tras la transacci贸n.
Las RSU vencen en su totalidad en el primer aniversario de la fecha de concesi贸n, por lo que la conversi贸n en acciones ordinarias est谩 supeditada a ese evento de adquisici贸n. El Formulario 4 divulga esta adjudicaci贸n de capital y el cambio resultante en la propiedad beneficiaria de la persona informante para mantener la transparencia ante la SEC.
Jeffrey G. Lamothe電� Aptevo Therapeutics (APVO)鞚� EVP 瓴� COO搿� 旮办灛霅橃柎 鞛堨溂氅�, 2025雲� 08/06鞚检棎 17,300臧滌潣 鞝滍暅臁瓣贝攵� 欤检嫕雼渼(RSU)毳� 攵�鞐皼鞎橃姷雼堧嫟. 臧� RSU電� 氤错喌欤茧 1雽�1 鞝勴櫂霅橂┌, 鞚� 攵�鞐姅 氤搓碃霅� 臧�瓴� $0.00搿� 韺岇儩歃濌秾 旆摑鞙茧 旮半霅橃棃瓿�, 鞝滌稖 靹滊電� 瓯半灅 頉� 17,300欤检潣 歆侅爲鞝� 靾橃澋 靻岇湢毳� 氤挫棳欷嶋媹雼�.
鞚� RSU電� 攵�鞐澕鞚� 觳� 氩堨Ц 旮半厫鞚检棎 鞝勳暋 臧�靻�(vest)霅橂瘈搿� 氤错喌欤茧鞚� 鞝勴櫂鞚� 頃措嫻 臧�靻� 鞚措菠韸胳棎 霐半澕 鞚措（鞏挫雼堧嫟. Form 4電� 鞚� 欤检嫕 氤挫儊瓿� 氤搓碃鞚胳潣 靾橃澋 靻岇湢甓� 氤�霃欖潉 SEC鞚� 韴獏靹� 頇曤炒毳� 鞙勴暣 瓿奠嫓頃╇媹雼�.
Jeffrey G. Lamothe, indiqu茅 comme EVP et COO d'Aptevo Therapeutics (APVO), s'est vu attribuer le 08/06/2025 17 300 unit茅s d'actions restreintes (RSU). Chaque RSU se convertit une pour une en actions ordinaires ; l'attribution est enregistr茅e comme une acquisition de titres d茅riv茅s au prix d茅clar茅 de 0,00 $, et le d茅p么t indique 17 300 actions de propri茅t茅 directe 脿 la suite de la transaction.
Les RSU acquerront int茅gralement leurs droits au premier anniversaire de la date d'attribution, de sorte que la conversion en actions ordinaires d茅pendra de cet 茅v茅nement d'acquisition (vesting). Le formulaire 4 divulgue cette attribution d'actions et la variation correspondante de la propri茅t茅 b茅n茅ficiaire de la personne d茅clarante afin d'assurer la transparence vis-脿-vis de la SEC.
Jeffrey G. Lamothe, ausgewiesen als EVP und COO von Aptevo Therapeutics (APVO), erhielt am 08.06.2025 17.300 Restricted Stock Units (RSUs). Jede RSU wandelt sich eins zu eins in Stammaktien um; die Zuteilung ist als Erwerb von Derivatwertpapieren zum gemeldeten Preis von $0.00 erfasst, und die Einreichung weist nach der Transaktion 17.300 Anteile direkten wirtschaftlichen Eigentums aus.
Die RSUs werden am ersten Jahrestag der Zuteilung vollst盲ndig frei (vest), sodass die Umwandlung in Stammaktien von diesem Vesting-Ereignis abh盲ngig ist. Formular 4 legt diese Aktienzuteilung und die daraus resultierende 脛nderung des meldepflichtigen wirtschaftlichen Eigentums zur Transparenz gegen眉ber der SEC offen.
- None.
- None.
Insights
TL;DR A time鈥慴ased RSU grant of 17,300 shares was reported as direct beneficial ownership; vesting is one year.
The filing documents a standard executive equity award: 17,300 RSUs that convert one鈥慺or鈥憃ne into common stock and vest in full after one year. The award is recorded at a $0.00 price and is reported as direct beneficial ownership upon grant. From a governance disclosure perspective, the Form 4 provides the required transparency about the change in insider holdings and the vesting schedule; it does not disclose any performance conditions or alternative vesting terms.
TL;DR The grant increases the executive's potential shareholding by 17,300 RSUs with a one鈥憏ear time vest.
The instrument is a Restricted Stock Unit converting one鈥慺or鈥憃ne into common stock, with all 17,300 units vesting on the first anniversary of the grant date. The reported $0.00 price indicates no cash payment for the award at grant. The filing does not provide valuation, grant rationale, or details on whether the grant is part of a broader compensation plan, so assessment of materiality or cost to the company cannot be determined from this document alone.
Jeffrey G. Lamothe, indicato come EVP e COO di Aptevo Therapeutics (APVO), ha ricevuto il 08/06/2025 17.300 restricted stock units (RSU). Ogni RSU si converte uno a uno in azioni ordinarie; la concessione 猫 registrata come acquisizione di titoli derivati a un prezzo riportato di $0.00, e il deposito mostra 17.300 azioni di propriet脿 diretta a seguito della transazione.
Le RSU maturano integralmente al primo anniversario della data di attribuzione, quindi la conversione in azioni ordinarie 猫 subordinata a tale evento di maturazione. Il Modulo 4 comunica questo premio azionario e la conseguente variazione della propriet脿 effettiva della persona che effettua la comunicazione per garantire la trasparenza verso la SEC.
Jeffrey G. Lamothe, identificado como EVP y COO de Aptevo Therapeutics (APVO), recibi贸 el 08/06/2025 17.300 unidades restringidas (RSU). Cada RSU se convierte una a una en acciones ordinarias; la concesi贸n se registra como adquisici贸n de valores derivados a un precio declarado de $0.00, y la presentaci贸n muestra 17.300 acciones de propiedad directa tras la transacci贸n.
Las RSU vencen en su totalidad en el primer aniversario de la fecha de concesi贸n, por lo que la conversi贸n en acciones ordinarias est谩 supeditada a ese evento de adquisici贸n. El Formulario 4 divulga esta adjudicaci贸n de capital y el cambio resultante en la propiedad beneficiaria de la persona informante para mantener la transparencia ante la SEC.
Jeffrey G. Lamothe電� Aptevo Therapeutics (APVO)鞚� EVP 瓴� COO搿� 旮办灛霅橃柎 鞛堨溂氅�, 2025雲� 08/06鞚检棎 17,300臧滌潣 鞝滍暅臁瓣贝攵� 欤检嫕雼渼(RSU)毳� 攵�鞐皼鞎橃姷雼堧嫟. 臧� RSU電� 氤错喌欤茧 1雽�1 鞝勴櫂霅橂┌, 鞚� 攵�鞐姅 氤搓碃霅� 臧�瓴� $0.00搿� 韺岇儩歃濌秾 旆摑鞙茧 旮半霅橃棃瓿�, 鞝滌稖 靹滊電� 瓯半灅 頉� 17,300欤检潣 歆侅爲鞝� 靾橃澋 靻岇湢毳� 氤挫棳欷嶋媹雼�.
鞚� RSU電� 攵�鞐澕鞚� 觳� 氩堨Ц 旮半厫鞚检棎 鞝勳暋 臧�靻�(vest)霅橂瘈搿� 氤错喌欤茧鞚� 鞝勴櫂鞚� 頃措嫻 臧�靻� 鞚措菠韸胳棎 霐半澕 鞚措（鞏挫雼堧嫟. Form 4電� 鞚� 欤检嫕 氤挫儊瓿� 氤搓碃鞚胳潣 靾橃澋 靻岇湢甓� 氤�霃欖潉 SEC鞚� 韴獏靹� 頇曤炒毳� 鞙勴暣 瓿奠嫓頃╇媹雼�.
Jeffrey G. Lamothe, indiqu茅 comme EVP et COO d'Aptevo Therapeutics (APVO), s'est vu attribuer le 08/06/2025 17 300 unit茅s d'actions restreintes (RSU). Chaque RSU se convertit une pour une en actions ordinaires ; l'attribution est enregistr茅e comme une acquisition de titres d茅riv茅s au prix d茅clar茅 de 0,00 $, et le d茅p么t indique 17 300 actions de propri茅t茅 directe 脿 la suite de la transaction.
Les RSU acquerront int茅gralement leurs droits au premier anniversaire de la date d'attribution, de sorte que la conversion en actions ordinaires d茅pendra de cet 茅v茅nement d'acquisition (vesting). Le formulaire 4 divulgue cette attribution d'actions et la variation correspondante de la propri茅t茅 b茅n茅ficiaire de la personne d茅clarante afin d'assurer la transparence vis-脿-vis de la SEC.
Jeffrey G. Lamothe, ausgewiesen als EVP und COO von Aptevo Therapeutics (APVO), erhielt am 08.06.2025 17.300 Restricted Stock Units (RSUs). Jede RSU wandelt sich eins zu eins in Stammaktien um; die Zuteilung ist als Erwerb von Derivatwertpapieren zum gemeldeten Preis von $0.00 erfasst, und die Einreichung weist nach der Transaktion 17.300 Anteile direkten wirtschaftlichen Eigentums aus.
Die RSUs werden am ersten Jahrestag der Zuteilung vollst盲ndig frei (vest), sodass die Umwandlung in Stammaktien von diesem Vesting-Ereignis abh盲ngig ist. Formular 4 legt diese Aktienzuteilung und die daraus resultierende 脛nderung des meldepflichtigen wirtschaftlichen Eigentums zur Transparenz gegen眉ber der SEC offen.
FAQ
What did APVO insider Jeffrey Lamothe acquire?
When do the RSUs vest for APVO (APVO) insider?
What ownership change was reported for APVO (APVO)?
Was there any cash paid for the RSUs in the Form 4?
Is the transaction tied to a performance condition or 10b5鈥�1 plan?
